Anti-Psychotic Drug Could Prolong The Lives of Amyotrophic Lateral Sclerosis Patients
Pexels / Pixabay

Anti-Psychotic Drug Could Prolong The Lives of Amyotrophic Lateral Sclerosis Patients

According an article from CityNews Toronto, an anti-psychotic medication is undergoing clinical trials in the treating of amyotrophic lateral sclerosis. In other studies, the treatment has shown to help slow…

Continue Reading Anti-Psychotic Drug Could Prolong The Lives of Amyotrophic Lateral Sclerosis Patients
The First Treatment in History for Mucopolysaccharidosis VII Was Just Approved by the FDA
source: pixabay.com

The First Treatment in History for Mucopolysaccharidosis VII Was Just Approved by the FDA

According to a story from EParent, the pharmaceutical company Ultragenyx released a statement confirming that the company's product MEPSEVII had received approval for public use by the Food and Drug…

Continue Reading The First Treatment in History for Mucopolysaccharidosis VII Was Just Approved by the FDA
Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University
https://pixabay.com/en/gold-medal-winner-swimming-381749/

Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University

Ellie Simmonds is a dominate Paralympic swimmer having won five times in her 23-years and was honored locally for her success, reported Border Telegraph.  Just recently, she attended to a…

Continue Reading Ellie Simmonds, Paralympic Champion, Receives Honorary Degree From Swansea University
Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
Source: Pixabay

Midatech Pharma Gets Verbal Approval For MTD201 Continued Development

Midatech Pharma just received verbal confirmation from Polish regulators to conduct the first European in-human study for a treatment that could potential aid those with carcinoid cancer and acromegaly, reported…

Continue Reading Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis
source: pixabay.com

PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis

According to a story from CBC News, Jillian Lanthier's son Landen Alexa was diagnosed with a severe and rare form of juvenile idiopathic arthritis at six years old. Although he…

Continue Reading PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis
This Tournament is Raising Money for Colitis and Crohn’s Disease Research
source: pixabay.com

This Tournament is Raising Money for Colitis and Crohn’s Disease Research

According to a story from Syosset Jericho Tribune, the charity basketball fundraiser called Hoops for Harrison is back again this year. The tournament was named after Harrison Gillman, who now…

Continue Reading This Tournament is Raising Money for Colitis and Crohn’s Disease Research
A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA
source: pixabay.com

A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA

According to a story from ANCA Vasculitis News, The European Medicines Agency just approved the pharmaceutical company ChemoCentryx's application for the marketing of avacopan as a potential treatment for anti-neutrophil…

Continue Reading A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA
Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions
Source: Pixabay

Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions

RespireRx Pharmaceuticals announced last month it was cleared to resume its ampakine CX717 clinical trials to evaluate the drug’s efficacy in several central nervous system and respiratory disorders, including Pompe…

Continue Reading Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions